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ABSTRACT
APPLICATION OF LINEAR MIXED-EFFECTS MODELS
TO CROSSOVER DESIGNS
LeiZhou
November 29,2012
Crossover design is a type of longitudinal study with each subject receiving different
treatments in different time periods. It has been used frequently in the pharmaceutical
industry and other medical fields to investigate the safety and efficacy of new drugs or
new treatments. For crossover studies, the treatment effects from the earlier period may
be carried over to the later period, which is called the carry-over effect, the response may
naturally change over different periods. How to assess treatment effect with accounting
for all these features deserves further investigation.
Linear mixed-effects (LME) model has been widely applied to analyze data resulted
from longitudinal studies. In this project, we model treatment effects, period effects, and
carryover effects using the LME for 2x2 crossover studies, where all subjects are
randomly assigned to two sequences, and each subject is treated subsequently with two
treatments, the order of the treatments depends on its sequence. We first investigated the
simple 2x2 design, where each subject has only one response measurement under each
treatment. Extensive simulations were carried out to compare the performance between
LME and the traditional Grizzle's method. We extend the LME to the general2 x 2
crossover studies, where the response under each treatment is taking over different time
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point. We applied our model to an endothelial progenitor cell (EPC) study, where each
patient was exposed to either air (placebo) first then airborne particular matters (PM) or
PM first then air. In each exposure condition, the EPC cells were measured right before
the exposure (Pre), right after the exposure (Post), and the second day follow-up (FU).
The results obtained from LME and traditional methods are compared.

v

TABLE OF CONTENTS

ACKNOWLEDGEMENTS ........................................................................ .iii
ABSTRACT ......................................................................................... .iv
LIST OF TABLES ................................................................................. viii
LIST OF FIGURES ................................................................................. .ix
CHAPTER 1. INTRODUCTION .................................................................. 1
1.1 Crossover trial. ....................................................................................... 1
1.2 Baseline measurements ....................................................................... 3
1.3 Mixed-effects models ......................................................................... 3
CHAPTER 2. STATISTICAL METHODS FOR 2x2 CROSSOVER STUDIES WITH A
SINGLE OBSERVATION PER PERIOD ........................................................ 5
2.1 Crossover design ............................................................................... 5
2.2 Grizzle's method .............................................................................. 6
2.3 LME model. ................................................................................. .1 0
2.4 Case studies .............................................................................................................. 11
2.4.1 Case study 1: PEFR data ............................................................. 11
2.4.2 Case study 2: FEVI data ............................................................ .12
2.5 Simulations ................................................................................... 15
2.6 Results and conclusions ..................................................................... 18

vi

CHAPTER 3 STATISTICAL METHODS FOR 2x2 CROSSOVER STUDIES WITH
MULTIPLE OBSERVATIONS PER PERIOD ................................................. 19
3.1 Introduction .................................................................................. .19
3.2 LME method ................................................................................. 20
3.3 Byron Jones's analysis method ............................................................ 21
3.4 Case study ..................................................................................... 22
3.5 Discussion and conclusion ................................................................. .26
CHAPTER 4 DISCUSSION AND FUTURE WORK .......................................... 27
REFERENCES ...................................................................................... 28
APPENDIX: R CODE FOR THE THESIS ...................................................... 30
CURRICULUM VITAE ........................................................................... 37

vii

LIST OF TABLES
TABLE
I. Description of crossover design trials ......................................................... 5
2. The fixed effects in the full model.. .......................................................... 6
3. Estimations of fixed effects components for linear mixed-effects model for PEFR
data .............................................................................................. .12
4. Estimations of fixed effects based on LME for FEVI data ............................... 15
5. Simulations results for LME model and Grizzle's method for the scenario without
carryover effects (~12=O) ............................................................................................. 16
6. Simulations results for LME model and Grizzle's method for the scenario with small
carryover effects (~I2=O.5) ..................................................................... 16
7. Simulations results for LME and Grizzle's method for the scenario with large
carryover effects (~12=1.0) ................................................................... .17
8. Expectations of responses for each sequence with baseline ............................... 21
9. R for AIRIPM data based on LME ........................................................... 25

viii

LIST OF FIGURES
FIGURE
1. Illustration of2x2 crossover design ...................................................... .1
2. Subject-level profiles under group AB and BA for PEFR data ...................... 11
3. Treatment A versus Treatment B for FEVI data ...................................... 13
4. Subject-level profiles under group AB and BA for FEV1 data ...................... .14

S. Comparisons of powers of the two methods for different group sizes and different
carry-over effects .......................................................................... .17
6. Subject-level profiles under "CD31 +CD34+/SOK lymph" ........................... .23
7. Treatment profile for all subjects (exclude "Pre") for PM!AIR data ................ 23
8. Comparison between PM and AIR in different sequences ........................... .24

ix

CHAPTER 1
INTRODUCTION

Crossover trial

1.1

There are two commonly used study designs in clinical research: parallel design and
crossover design. In a parallel study design, each subject is randomly assigned to one and
only one treatment. A crossover design study is a longitudinal study in which each
subject receives a sequence of different treatments, and there is a "washout" period
between two treatments. Crossover designs are common for experiments in many
scientific disciplines such as psychology, education, pharmaceutical science, and
healthcare, especially medicine [1]. If the disease is chronic and the effect of treatment is
reversible, a crossover trial may be an attractive option [2].
We first focus on the simple 2x2 crossover design, in which there are two treatments,
traditionally labeled A and B, and two periods. Each subject receives the treatments in
either of the two possible sequences, AB or BA. This kind of design is shown in Figure

1[3].

Group 1
Washout

Treatment A

Group 1
Treatment B

Start
(baseline)

Group 2

Group 2
Washout

Treatment B

Figure 1. Illustration of2x2 crossover design
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Treatment A

The treatment effect is estimated using the differences of the pairs of observations
from each subject. Usually, equal numbers of subjects are randomly assigned to the two
groups. A crossover trial has two advantages over a non-crossover trial. First, the
influence of confounding covariates is reduced because each subject serves as his or her
own control [4]. In a non-crossover trial, such as randomized clinical trials, different
treatment groups are often found to be unbalanced on some covariates. Second, optimal
crossover designs are statistically efficient and require few subjects than do noncrossover designs. The so-called "optimal design" refers to such kind of experimental
design which allows parameters to be estimated without bias and with minimum variance
[4]. By contrast, a non-optimal design requires a greater number of experimental runs to
estimate the parameters with the same precision as an optimal design. In practice, optimal
designs can reduce the costs of experiments. An obvious deficiency of this design is the
possible existence of "carry-over", which means that the data from the second period may
reflect not only the effect of the treatment given in that period but also the residual effect
of treatment given in the previous period [5]. The presence of a differential carry-over
effect, if ignored, may cause biased estimate for the treatment effects. In general, the
carryover effect is first examined before testing treatment effects. The test for the
presence of carry-over effect is usually carried out using the unpaired t test for the two
groups based on the sums of within-subjects observations. However, this test could be
less powerful [4]. In that case, we may have to increase sample size, which will exactly
offset the advantage of efficiency provided by the crossover designs.
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1.2 Baseline measurements
The statistical power of crossover trial may be increased by taking "baseline"
measurements of the outcome variable at the start of each treatment period. If changes
from baselines are to be analyzed, the between-subject variation will be removed and the
power of tests will be increased [6]. Analysis of covariance (ANCOVA) has been
recommended [6] by taking best advantage of baseline measures, as this method
explicitly estimates the association between baseline and post-treatment measurements.

1.3 Mixed-effect models
A mixed-effect model is a statistical model containing both fixed effects and random
effects, where random effects are often used to describe the subject-specific effect, while
fixed effects are used to describe population-level effect. Mixed effect models are
particularly useful in settings where repeated measurements are taken on the same
statistical units, or where measurements are made on clusters of related statistical units
[7]. The correlation between the repeated measurements is captured by the random
effects and their distribution assumption [4]. Furthermore, the mixed-effects model can
handle missing and unbalanced data, which are common in practice, especially for
longitudinal data analysis [7].
In this thesis, we applied linear mixed-effects models to our recent 2x2 crossover
experimental data on examining whether exposure to airborne particulate matter (PM)
affects the circulating levels of endothelial progenitor cell (EPC) populations. Subjects
are randomly assigned to two exposure sequences: one with AIR first then followed by
PM, the other with PM first then followed by AIR. Under each exposure, the blood
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sample was taken before exposure (Pre), two-hours after exposure (Post), and the second
morning for follow-ups (FU). In an exposure sequence, the second exposure was carried
out one week after the first exposure. Flow cytometry was applied to measure the cell
counts for CD31 +CD34+ ISOK lymph.

4

CHAPTER 2
STATISTICAL METHODS FOR 2x2 CROSSOVER STUDIES WITH A SINGLE
OBSERVATION PER PERIOD
2.1 2x2 crossover design studies
In 2x2 crossover design studies, subjects are randomly assigned either to sequence 1,
where each subject receives treatment A in the first period followed by treatment B in the
second period; or to sequence 2, where each subject receives the two treatments in the
reverse order. (See Table 1):
' t na
. Is
' f 0 f crossover d
T able 1. D escnpllon
eSlgn
Period 1
Sequence
1 (Group 1)
A
2 (Group 2)
B

Period 2
B
A

The two periods should be the same length of time and usually the same numbers of
subjects are allocated to both groups. The run-in measurement, which is prior to the first
given treatment, is always obtained as baseline measurement to deal with the recruitment
variance. The washout period is set between two periods, which is expected to be long
enough to eliminate the extra effect brought to the second period by the first treatment in
the first period, (i.e., carry-over effect). The variables are denoted as below: Yikj is the
observation for ith sequence (i=I,2) jth subject G=I,2, ...... ni) kthperiod (k=I,2); J.l is the
overall mean; 't is the treatment effect; 1t is the period effect; A is the carry-over effect; s is
random subject effect, which is assumed to be a random variable with mean zero
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and variance a/; e is a within-subject error, which is assumed to be random variable with
mean zero and variance if.
In this chapter, we first introduce the procedure of traditional Grizzle's method for 2x2
crossover design studies, then introduce the linear mixed-effect (LME) model. A case
study was carried out by using both methods. At last, simulations are carried out to
compare the performance of both methods.

2.2 Grizzle's method
In the traditional2x2 crossover design, the following parameters are usually
introduced: 'tI and 't2 are treatment parameters for treatment A and B, respectively; XI and
X2 are period parameters for period 1 and 2; AI and A2 are carry-over parameters. The
expected effect in each group and each period are displayed in Table 2:
Table 2. The fixed effects in the full model
Period 1
Sequence
1 (AB)
1.1 + XI + 'tI
2 (BA)
1.1 + XI + 't2

Period 2
1.1 + X2 + 't2 + AI
1.1 + X2 + 'tI + A2

This parameterization can be obtained by the following model:
Yijk = Jl + Xk + 'tu + Av + Sij + Eijk

(1)

Where Yijk is the observation for ith sequence (i=1,2) jth subject G=1,2, ...... ni) kthperiod
(k=1,2); Jl is the overall mean; Xk is the effect of the kth period (k=1,2); 'tu represents the
effect of the uth treatment (u=A, B);

Av represents the residual effect of the vth treatment

in the first period on the response in the second period (v=A, B); Sij is the effect fo thejth
subject in the ith group (i=1,2;j=1,2, ..... n); Eijk is the within-subject error forjth subject
in the ith group and the kth period.
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Here we assume that 1-1, 1tk, 'tu , and J.v.. are fixed effect, Sij is an random effect with mean
zero and variance

a/, and 8ijk is a random error with means zero and variances c?, and Sij

and 8ijk are mutually independent. Thus, the between-subject variance is as 2 and the
within-subject variance is a 2• Assume that the within-subject correlation is p, the
variance-covariance matrix is given as:

This variance structure is called uniform or compound symmetry structure.
In a crossover design, the measured effect from the second period may reflect not only
the treatment given in that period but also the residual effect of treatments given in the
first period. This phenomenon is referred to as "carry-over" effect [4].
When the carry-over effect exists, the evaluation for treatment effect without
considering the carry-over effect may result in a biased estimate. Grizzle (1965) proposed
first test carry-over effect using the sums of the pairs of observations from each subject:
tlj

= Yljl + Ylj2

for the jth subject in sequence (group) 1

+ Y2j2

for the jth subject in sequence (group) 2

t2j = Y2jl

To test iff"l = 1..2, we can use two-sample t test to test whether the summations in
sequence 1 is significantly different from the summation in sequence 2. That is:
(2)

(3)
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The pooled sample variance is [4]:

The test statistic for carry-over effect is:
~

~

05

T", = Ad / (Var [AdD' - ~nl+n2-2)

(4)

This test is criticized as lacking power to detect sizable carry-over effect because of
the usage of between-subject comparison. Grizzle (1965) recommended that the test be
performed at a significance level greater than the traditional value of 0.05, for example
0.1 or even 0.15 [4]. Since the low power, we should be careful and cannot assert that the
lack of significance implies lack of carry-over effect [8].
The treatment effect is estimated using the differences of the pairs of observations
from each subject, which is a relatively powerful test (CROS) [4]. The unbiasedness of
the resulting estimate rests on the assumption of equality of the carry-over effects. If the
test of carry-over effects is significant, Grizzle (1965) suggested that only the data from
period 1 should be used to test the treatment effects, as in a parallel groups design (PAR)

[4].
Grizzle proposed the following strategy to analyze 2x2 crossover design studies [9].
First, test whether there is a carry-over effect at type I error level of a= 0.1. If the test is
not rejected, one then tests the treatment effects using CROS at type I error level of a=
0.5; if the test for carry-over effect is rejected, test treatment effects using PAR at type I
error level of a= 0.5. This has come to be known as "the two-stage procedure" (TS). The
reasons can be verified by the following mathematical derivations.
If we can assume that there is no carry-over effect (i.e. Al = 1..2), then the period
differences are:
8

d lj = Yljl

d2j =

- Ylj2

for the jth subject in sequence (group) 1

Y2jl - Y2j2

for the jth subject in sequence (group) 2

We have:

We use the two-sample t test to test treatment effect by using the period differences:

(5)
One can easily see that:

(6)
The pooled sample variance is [4]:

The test statistic for treatment effect is constructed as:

(7)
If we cannot assume that there is no carry-over effect (i.e. A.I f. A.2), then:

That is, Td is no longer an unbiased estimator of'td if A.ct = Ai - A2f.O [4]
Since Xct = }TIL + }Tl2. - }T21. - }T22, and Td = ~ [}TIL - }Tl2. - }T21. + }T22.l, we have

That is the difference between the groups in terms of their first period means. In other
words, if A.ct f.O then the estimator of'td is based on between-subject information and is the
estimator we would have obtained if the trial has been designed as a parallel study.
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2.3 Linear mixed-effects models for 2x2 crossover design
Since the main purpose of the crossover study is to investigate treatment effects, we
consider a linear mixed effect model which directly models the treatment effect.
Meanwhile, we introduce period effect and carry-over effect. Instead of using two-step
procedure, we directly estimate the parameters involved, and test whether there is
treatment effect based on the results obtained from LME model. The model can be
described by:
Yijk = ~o + ~lXtreat +~2Xperiod +~12 X treat Xperiod + Sij +eijk
Sij

is a random subject effect term and sij is assumed to be independently and identically

distributed with N(O, 6/)
eijk is

error term and is assumed to be independently and identically distributed with

N(O, 6 2)
Two dummy variables are introduced as:
X treat =

1if the subject is in treatment B, and Xtreat = 0 otherwise;

Xperiod =

1if the subject is in period 2, and Xperiod = 0 otherwise.

Introducing random subject effects in the regression model can capture the withincorrelation of the subject observations. In addition, random subject effects could recover
the information in the subject totals [4]. However, if there is little variation in the subject
totals, the between-subject variation will be small and the random effect may not need to
be included. The variation can often be described by the intraclass correlation, which is
defined as

os2 /

(0/ +(2) [4], meaning the size ofthe between-subject variance (os2)

relative to the within-subject variance (if). In many crossover trials, we expect the
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between-subject correlation is large and the remaining within-period correlation is small
and in many cases quite close to zero [10].

2.4 Case studies
2.4.1 Case study 1: PEFR data
We apply Grizzle's method and LME to analyze PEFR data which were from a
randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of
an inhaled drug (A) given twice daily via an inhaler in patients with chronic obstructive
pulmonary disease (COPD). The eligible patients were randomized to receive either Drug
(A) or Placebo (B) twice daily for 4 weeks. The patients then switched over to the
alternative treatment for an additional 4 weeks. Peak Expiratory Flow Rate (PEFR) was
measured as the response variable.
The raw data for sequence AB and BA are illustrated in Figure 2. From Figure 2, we
expect that A is higher than B.
B: sequence BA

A: sequence AS

-

-

-------=
==

g
..,

=

~-

.......
~

:;;;--

~

------==

A

B

A

B

Figure 2. Subject-level profiles under group AB and BA for PEFR data
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First, we apply Grizzle's method to examine the treatment effect for PEFR data. To do
that, we first test the carry-over effects.
Xd = f\. - f2. = 38.89, var(X d )= 1681.68, and
TA =38.89/(1681.68)°·5 = 0.9483
P-value=2*P(T A> 1(0.975,54») = 0.347, therefore, we conclude that there is no carry-over
effect.
We corne to test the treatment effects under the assumption of equality of carry-over
effects (i.e. no carry-over effect).
A

1

-

-

~

Td = 2" (d\. - d 2) = 10.4, Var (Td) = 11.666, and
T t = 10.4/(11.666)°·5 = 3.045
P-value=2*P(T t> t(0.975,54») = 0.004
Therefore, we conclude that there is a significant treatment effect.
We apply LME method to PEFR data.
The LME model is as follows:

Xtreat=1 when given drug (A), 0 otherwise; X period=1 for second period, 0 otherwise.
The results based on LME are summarized in Table 3. The results are similar to those
based on Grizzle's method.
Table 3. Estimations of fixed effects components for linear mixed-effects model for
PEFRdata
SE
t-value
p-value
Estimate
DF
10.527
o
22.396
235.769
55
Bo
-3.046
3.416
0.004
10.402
54
~ I (treatment)
3.416
1.103
54
0.275
3.767
~2 (period)
0.948
0.347
41.008
53
38.888
~ 12(interaction)

2.4.2 Case study 2: FEVl data
12

We also applied Grizzle's method and LME model to FEVI data by Patel (1983).
FEVI data was reported as being taken from the results of a trial involving subjects with
mild to acute bronchial asthma [4]. The treatments were single doses of two active drugs,
say A and B. The response of interest was the forced expired volume in one second
(FEV I)' The baseline FEV 1 measurement was taken during the run-in period immediately
prior to giving the first treatment. FEV 1 measurements were taken again, 2 and 3 hours
after treatment, the average of the two measurements is the observed measurement for
this period. A suitable period of time was then left before a second treatment was given.
The measurements from the second treatment were then taken at 2 and 3 hours to give
the average value for period 2. A general treatment profile is shown in Figure 3,

q
("')

treatment A
treatmentB
I()

N

(J)

q

Q)

N

::J
(0

>

>
w
u.

~
.....

5

10
subjectlD

Figure 3. Treatment A versus Treatment B for FEVI data
and the subject profiles in each group are shown in Figure 4
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Sequence AB

Sequence BA

q('C) -

q
('C)

o~

-

oq -

o~
~

____________

-

oq -

~

____________

B

B

A

~

~

A

Figure 4. Subject-level profiles under group AB and BA for FEVI data
According to treatment profile and the subject profile, treatment B may have higher
responses than treatment A.
We first analyzed the data using Grizzle's method:
We first tested the carry-over effect (Type I error is set as 0.1):

And the pooled sample variance is:
----;.
Var (Ad) =[ L

2

ni

-

. = 1 L k = l(tjk - tj.)

t

2

1

1

n1

n2

/ (nl+n2-2 )]* (- + -)=0.451

Therefore, T I. = Xd / (Var [Xd])o.s =-1.496~ ~14)
The p-value is 0.157, which is greater than 0.1, therefore, we are not able to reject the
null hypothesis on carry-over effect. We concluded that there is not carry-over effect.
Therefore we use eROS to test the treatment effects.
1 -

-

-

Td = "2 (dl. - d2) = -0.176, Var (Td) = 0.008, and
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T T = -0.176/(0.008)°·5 = -2.011. We get P-value= 0.064. Therefore, there is not
significant difference between the two treatments. We also analyzed the FEVI data
using LME model, the results are shown in Table 4. Based on Table 4, there is still not
significant difference for the period effects and treatment. Again, the results based on
Grizzle's method and LME are similar.
Table 4. Estimations of fixed effects based on LME for FEVI data
SE
DF
t-value
p-value
Estimate
~o
~I
~2

PI2

1.742
0.678
0.428
1.005

0.245
0.347
0.347
0.672

15
13
13
13

9.174
-1.956
-1.617
1.496

0
0.0723
0.1298
0.1584

2.5 Simulations
We generated the simulation data according to the following model:

Xtreat and Xperiod are

dummy-coded variables as specified in Section 2.3, and the

underlying regression coefficients are those obtained in the case study in Section 2.4
(Table 4.). The random subject effects are assumed to be normal distributed with mean
zero, variances 6/=0.428 and the within-subject is assumed to be normal with mean zero,
and variance 6 2=0.06. In simulations, each group was generated with 10 and 30 subjects,
respectively. First, we set

~I

=0, which means no treatment effect. We examined the

rejection rate for Ho: ~I=O over 1,000 times of simulations. Simultaneously, we also use
the Grizzle's method to analyze these randomly generated data and calculate the rejection
rate for carry-over effects and the rejection rate of tests for treatment effects. We repeated
the same process for ~12 =0 (i.e. no carry-over effect), ~12 =0.5 (i.e. small carry-over effect)
and ~12 =1 (i.e. large carry-over effect), and ~1=-0.6, -0.3, 0.3 and 0.6 treatment effects.
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The simulations results are summarized in Table 5 to 7, and in Figures 5.
In each table, the three columns under LME method are the fraction of rejection rate
(power), the mean of 1,000 estimated parameter PI, and the average standard deviation
(s.d.) for PI. The four columns under "Grizzle's method" are the rejection rate of carryover effects, the rejection rate of treatment effect being zero based on the Grizzle's
method (power), the average estimated treatment effect, and the average of standard
deviation (s.d.).
Table 5. Simulations results for LME and Grizzle's method without carryover effects
(P12=O)
LME
Grizzle's method
Carryover*
power est.
Power
est.
s.e.
s.e.
PI
-0.60
0.811 -0.586 0.195
0.119
0.940 -0.593 0.130
Group
0.118
size=10 -0.30
0.308 -0.302 0.199
0.948 -0.307 0.136
0.00
0.045 0.007 0.187
0.085
0.086 -0.002 0.113
0.30
0.305 0.299 0.196
0.115
0.943
0.302 0.133
0.60
0.831 0.603 0.191
0.083
0.972
0.602 0.113
0.999 -0.598 0.111
0.086
0.999 -0.603 0.069
Group
-0.60
0.755 -0.297 0.108
0.096
0.943 -0.296 0.072
size=30 -0.30
0.00
0.044 0.002 0.113
0.104
0.103
0.003 0.073
0.30
0.768 0.302 0.112
0.102
0.948
0.299 0.076
0.60
0.999 0.600 0.113
0.099
0.999
0.602 0.073
*The values in this column IS rejection rate for carryover effects tests.

Table 6. Simulations results for LME and Grizzle's method with small carryover
effects (1312=0.5)
LME
Grizzle's method
Carryover*
power est.
s.e.
Power
est.
s.e.
PI
0.998 -0.503 0.232
-0.60
0.826 -0.601 0.202 0.333
Group
0.762 -0.200 0.227
0.299 -0.299 0.197 0.349
size=1O -0.30
0.335
0.287
0.099 0.222
0.007 0.197
0.054
0.00
0.698
0.411 0.219
0.324
0.309 0.192 0.311
0.30
0.866
0.708 0.217
0.189
0.321
0.858
0.610
0.60
0.727
0.999 -0.570 0.151
0.999 -0.602 0.110
Group
-0.60
0.705
0.996 -0.262 0.153
0.111
0.739 -0.297
size=30 -0.30
0.340
0.047 0.154
0.685
0.051 0.009 0.112
0.00
0.742
0.338 0.158
0.688
0.114
0.741
0.300
0.30
0.638 0.153
0.707
0.999
0.999 0.602 0.111
0.60
*The values in this column is rejectIOn rate for carryover effects test
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Table 7. Simulations results for LME and Grizzle's method with large carryover effects
{P 12= 1.0)
LME
Grizzle's method
Power
est.
s.e.
Carryover*
power
est.
s.e.
PI
Group
-0.60
0.824 -0.588 0.193 0.796
0.997 -0.541 0.259
size=10 -0.30
0.301 -0.304 0.189 0.814
0.488 -0.256 0.259
0.00
0.047
0.010 0.192 0.791
0.228
0.059 0.263
0.30
0.312
0.303 0.195 0.804
0.346
0.349 0.262
0.60
0.823
0.604 0.200 0.795
0.820
0.650 0.267
Group
-0.60
0.999 -0.597 0.108
0.997
0.999 -0.597 0.110
size=30 -0.30
0.753 -0.298 0.112
0.996
0.754 -0.297 0.114
0.00
0.056
0.000 0.113 0.996
0.157
0.000 0.116
0.774
0.30
0.306 0.109 0.999
0.705
0.306 0.109
0.999
0.60
0.597 0.113 0.996
0.999
0.597 0.115
*The values III thIS column IS rejectIOn rate for carryover effects tests
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2.6 Results and conclusion
According to the above simulation results, we conclude that the significant level based
on LME method is maintained in the nominal level (i.e. 0.05) when

~l

is assumed to be

zero, no matter the different settings on group size or carryover effects.
While the Grizzle's method cannot maintain the significance level of 0.05 when there
is no treatment effect. The powers of the tests for both methods increase as

~l

increases.

We conclude that the linear mixed-effects model is more appropriate for the data
analysis of this kind of2x2 crossover designs.
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CHAPTER 3
STATISTICAL METHODS FOR 2x2 CROSSOVER DESIGNS WITH
MULTIPLE OBSERVATIONS PER PERIOD
3.1 Introduction
In this chapter we focus on the analysis of2x2 crossover design trials with repeated
measurements per period, that is, a sequence of observations are collected within the
same treatment period. The multiple observations over different time points on the same
subject could provide more information of response profile than a single measurement
[11]. The observations of each subject in 2x2 crossover designs in chapter 2 can also be
regarded as repeated measurements [4], as presented in Chapter 2.
It is known that the test of carry-over effects will generally be less powerful than that

of treatment effects because of the usage of between-subject comparison. One way
towards a solution of this problem is to include a "run-in" period and a "washout" period,
and to take measurements during these periods [8]. The run-in period precedes
administration of the first treatment and the wash-out follows the first treatment period. If
we assume that a measurement of the response is taken at the end of the run-in period and
at the end of the wash-out period, then these baseline measurements can be used to
provide a within-subject test of carry-over effects [8]. However, sometimes for ethical
reasons, a washout period is not possible and only the measurement of run-in period can
be taken. In this case, the first baseline measurement can be treated as a genuine covariate
because it cannot be affected by treatments. Thus, there are two options to make use of
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baseline measurements. One is to analyze the differences from the baseline measurements,
the other is to use the baseline as a covariates. The conventional analysis of the change
from baseline will provide unbiased least squares estimator of the direct treatment effects
[10]. We should realize that the carry-over effect of the first treatment on second baseline
measurement may not be equal to that on the measurement after receiving the second
treatment [12]. Ignoring it may cause the overestimation of the direct treatment effects. In
the case that there is a second baseline measurement, we should be very careful for the
two different orders of carry-over effects [4]. Baseline measurements can also be used as
covariates. It often happens in clinical trials that additional information is available for
each subject, such as age, sex, or weight [6]. These additional variables are usually called
covariates. One may wish to know if a treatment effect is related to the covariate. It is
possible that some of the between-subject variation can be accounted for by the covariate
value. Thus, by introducing the baseline as covariate, the between-subject residual
variance may be reduced [6].

3.2 LME method
In order to make the best use of baseline measurements, we first calculated differences
between after-treatment measurements and baseline measurements. The values of
differences are used to fit the LME model. It is possible that there may be different order
of carry-over effects for different time points within the same period. For the design with
two time points without counting for baseline measurement, the full model is:
Yijk =Po + P1Xtreat + P2 X time + Pl2 Xtreat .Xtime + OOXperiod +OIXperiod *Xtreat
+02Xperiod *Xtime +012X period*Xtime *Xtreat + Sij +Eijk
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where y represents the difference of the measurement after treatment from its baseline
measurement,

Sij

is random subject-effect, and sij is independently and identically

distributed with N(O, 6/),

€ijk is

a random error and is assumed to be independently and

identically distributed with N(O, 6 2).

3.3 Byron Jones's analysis method [4]
We come to examine the design with two after-treatment measurements plus baseline
measurement. The expectations of the responses in each group are summarized in the
following Table 8:
Table 8. Expectations of responses for each sequence with baseline
Sequence 1 (PM! AIR)
Sequence 2 (AIRlPM)
E(YllO)=Il-y+n1
E(Y21O)=Il+y+n1
E(YIII)=Il-y+n2-'t1
E(Y211)=Il+y+n2+t1
E(YI d=ll-y+n3-'t2
E(Y212)=Il+y+n3+t2
E(y 120)=Il-y+n4-8
E(Y220)=Il+Y-ht4+8
E(YI21)=Il-y+n5+'tI-AI
E(Y221)=Il+y+n5-'tI+AI
E(Y122)= ll-y+n6+t2-A2
E(Y222)= 1l+y+n6-'t2+A2

The parameter Il represents overall mean; the parameter 1t represents period effect,
where 1t1=1t2=1t3, 1t4=1t5=1t6; the parameter y represents group effect; the parameter 't
represents treatment effect, let us denote 'tl as the first-order treatment effect and 't2 as the
second-order treatment effect; the parameter 8 represents first-order carry-over effect; the
parameter Al and A2 represent second-order carry-over effect at two different time points.
Based on Jones's method, we carried out the following series of tests:
(i) test whether AI= A2; (ii) test whether Al or Al equals zero; (iii) test whether 8 equals
zero; (iv) test whether 't1='t2. We first obtain the least squares estimator for each
parameter of A, 8, and 't, all of which take the form of CI - C2, where Ci is a contrast
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among the six means from group i (i=l, 2). The estimators are defined by the following
contrasts:

O.,}- A2)1't,e: 0.5*(0, -1, 1,0, -1, 1), AI't,e: 0.5*(2, -1, 0, 0, -1, 0),
el't,A: 0.5*(1,0,0, -1,0,0), 'tle,A: 0.5*(1, -1,0,0,0,0,).
The two sample t tests are applied to test the carry-over effect and treatment effect.

3.4 Case study
We applied linear mixed-effects models to analyze the endothelial progenitor cell
(EPC) study. In this experiment, subjects were randomly assigned to two exposure
sequences: one with AIR first, and then followed by airborne particulate matter (PM); the
other sequence with PM first, and then followed by AIR. Under each exposure, the blood
sample was taken before exposure (Pre), two-hours after exposure (Post), and the second
morning for follow-ups (FU). In an exposure sequence, the second exposure was carried
out one week after the first exposure. Flow cytometry was applied to measure the cell
counts for CD31 +CD34+ 150K lymph. We plotted the response profile during the three
different time points of "Pre", "Post", "FU" to examine whether the response profile are
associated with different treatment (see Figure 6-8).
This experiment was crossover design because each subject received both treatments,
either in the sequence ofPMlAIR or reverse order. There are three measurements at three
different time points, namely baseline ("Pre"), tow-hour after treatment ("Post"), and the
second day morning follow-ups ("FU"). We adopted the analysis method of crossover
design to handle this experiment design. According to the definition of these time points,
the measurement of "Pre" was to be regarded as baseline measurement.
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Figure 8. Comparison between PM and AIR in different sequences
The difference between the measurement of "Post" and "Pre" (denoted by d.post),
and the difference between the measurement of "FU" and "Pre" (denoted by d.fu), were
the change score from baseline, which was considered as the responses at two different
time points. With the changes from baselines, we may be able to eliminate the possible
between-subject effect and the first-order carry-over effect, make use of more withinsubjects information to improve statistical power of test.
When we applied the LME to analyze the experiment data, we introduce the following
dummy variables in our model proposed in Section 3.2:
1 when given treatment of PM
X treat = { 0 when given treatment of AIR
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x. =
time

x .
penod

{10 when
when time point is Post
time point is FU

={ 1 when given treatment in period 1
0 when given treatment in period 2

The results based on LME are summarized in the following Table 9.
Table 9. LME model regression results summary for AIRIPM data
s Imate
Paramet er
Ef
SE
.. DF
t-vaIue
-38.23
52.25
28
-0.73
~o
78.30
28
-0.76
-59.82
~J (treat)
33.40
57.02
28
0.59
~2(time)
82.86
85.93
28
0.96
~dtrt*time)
-2.87
-224.65
78.30
28
Do(period)
DJ(period*trt)
281.37
128.62 28
2.19
D2(period *time)
115.57
85.93
28
1.35
-179.05
120.28 28
-1.49
DI2(per*trt*time)
2
6/(between-sub)
81.725
2
101.636
6 2(within-sub)

p-va ue
0.47
0.45
0.56
0.34
0.01
0.04
0.19
0.15

When we applied Jones's traditional method, we used the raw data and constructed
contrasts using the observations in the three time points, "Pre", "Post", and "FU. Seven
subjects were included in PM/AIR sequence and five subjects were included in AIRIPM
sequence. We calculated the contrasts in section 3.3 for each subject, and then obtained
the parameter estimates and pooled variance. Using the two-sample t test, we tested
whether there is carry-over effect and treatment effect. To test for the second-order carryover effect (Le. Ho: A1 - A2=0), the estimate ofA1 - A2 is 90.45, with a standard error of
38.90 on 12 degrees of freedom. The p-value of the t test is 0.042, indicating that the
second-order carry-over effect is significantly different between the two sequences. Then
we examined whether the first-order carry-over effects between the two sequences are
significantly different by testing whether 8=0. We have {j=-262.2, with a standard error
of 64.8 on 12 degrees of freedom. The p-value of the test is 0.002, indicating that the
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first-order carry-over effects are significantly different. That is, the first-order and
second-order carry-over effects are significantly different between the two sequences.
Therefore, we could only use the data in the first period (Yil.) to test the treatment effect.
To test the treatment effect (i.e. r-O), we have f=-62.68, with a standard error of 41.12 on
12 degrees of freedom. The p-value oft test is 0.158, indicating that there is no
significant difference between the two treatments.

3.5 Discussion and conclusion
For this case study, we got similar results using both LME model and Jones's method.
We conclude that the carry-over effects are extremely significant and the treatment
effects are no significant different. However, LME models use all collected data and
model the treatment effect, period effect and different order carry-over effects
simultaneously. While Jones's method uses two-stage tests: first test carry-over effect,
then test treatment effect based on whether carry-over effect is significant. We expect
LME will be more power for testing treatment effect.
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CHAPTER 4
DISCUSSION AND FUTURE WORK
A linear mixed-effects model (LME) includes both containing both fixed effects and
random effects. It is particularly useful in analyzing repeated measurements, where the
measurements between within-subject observations can be captured by random effect.
The mixed-effects models can use all available data, no matter whether the subject has
completed observations. LME has performed better than the traditional methods.
In this thesis, we first analyzed the classic 2x2 crossover data using LME model and
traditional Grizzle's method. We carried out simulations for both methods to compare
their performances. The LME model performs better than Grizzle's method in terms of
maintaining the type I error rate. We extend LME to crossover data with multiple
measurements within each period. The LME model is easy to implement. In addition, we
applied the method suggested by Byron Jones to the 2x2 crossover design with multiple
observations within each period. The required t tests are based on the constructed
contrasts. After carrying out different t tests, we obtained the similar results as LME
models. LME models are easy to implement, preserve the type I error rate. LME models
are recommended for the crossover designs.

It is also noticed that we have not carried out simulations to compare the LME and
Jones's method, we are still working on it and will present it in someplace else.
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APPENDIX: R code for the thesis

************************************************************************
Plot for PEFR data

************************************************************************
PEFR<-read. table ("c:/PEFR. txt",header=T)
par (mfrow=c (1, 2))
forO in 1:27) {
plot (PEFR$Perl [i] :PEFR$Per2[i], type="l",
ylim=c(100,500),xlab="",ylab="",main="sequence AB")
par (new=TRUE)
}

plot (mean (PEFR$Perl [1:27]) :mean(PEFR$Per2[1:27]),
type="1",col=2,lwd=4,ylim=c(100,500))
for(i in 28:56) {
plot (PEFR$Per1[i] :PEFR$Per2[i], type="l", ylim=c(100, 500),
xlab="",ylab="",main="sequence BA")
par (new=TRUE)
}

plot (mean (PEFR$Perl [28:56]) :mean(PEFR$Per2[28:56]),
type="1",col=3, lwd=4, ylim=c(100,500))

************************************************************************
Plot and analysis for FEV data using LME

************************************************************************
1i brary (n lme)

rr<-read. table("c:/rr. txt",header=T)
rr
attach (rr)
value<-rep(0,32)
for(i in 1:16){
value[2*i-1]<-period1[i]
value[2*i]<-period2[i]
}

period
subject<-rep(c(1:16), each=2)
subject
period<-rep(c(O, 1), 16)
period
trt<-c(rep(c(0,1),8),rep(c(1,0),8))
trt
FEV<-data. frame (subject, trt, period, runin, value)
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FEV
FEV.ANA<-lme(value~runin+trt*period,random=~1Isubject,data=FEV)

summary (FEV. ANA)
plot(FEV$value[FEV$trt==0],type="1",lty=1)
par (new=TRUE)
plot (FEV$value[FEV$trt==1], type="l", lty=2,col=2)
legend (0, 3. 5, legend=(c("treatment A", "treatment 8"», Ity=c(1,2»
par (mfrow=c (1, 2»
forO in 1:8) {
plot (FEV$value[(2*i-1) : (2*i)], type="1",col=i,ylim=c(0.5,3),ylab="")
par (new=TRUE)
}

par (new=FALSE)
for(i in 9: 16) {
plot (FEV$value[(2*i-1) : (2*i)],type="1",col=i,ylim=c(0.5,3),ylab="")
par (new=TRUE)
}

************************************************************************
Analysis of FEV data using Grizzle's method
************************************************************************
sum<-rep(NA,16)
for 0 in 1: 16) {
sum[i] <-FEV$value [2*i-1] +FEV$value[2*i]
}

sum
mean. t<-mean()-mean(sum[9:16])
mean. t
var. t<-sqrt((var(sum[1:8])*7+var(sum[9:16])*7)/14*0.25)
var. t
T<-mean. t/var. t
T

pvalue<-2*pt(-abs(T),14)
pvalue
diff<-rep(NA,16)
for (i in 1: 16) {
diff[i] <-FEV$value[2*i-1]-FEV$value[2*i]
}

diff
mean. diff<-(mean(diff[1:8])-mean(diff[9:16]»*0. 5
mean.diff
var.diff<-sqrt((var(diff[1:8])*7+var(diff[9:16])*7)/14*0.25/4)
var. diff-2
T. diff<-mean.diff/var.diff
T.diff
pvalue<-2*pt(-abs(T. diff), 14)
pvalue
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************************************************************************
Simulations
************************************************************************
1i brary (n Ime)
beta. treat. Ime<-beta. treat. tra<-reject. Ime<-reject. tra<-c()
betaO<-1.7416; beta1<-0; beta2<-0.4275; beta12(--1.005
TC<-Period<-Sub<-y<- meandiff. sum<-var. sd<-yy.mean<-beta1. Ime<-c()
n1<-n2<-10
aa<-rep(NA,1000)
## iter<-l
Count.carry<-Count. trad<-O
for (i ter in 1: 1000) {
TC<-Period<-Sub<-y<-c()
for (j in l:nl)
{Sub<-c(Sub, rep(j, 2»
TC<-c(TC, #T", "C")
Period<-c(Period, 1,2)
sl<-rnorm(l, 0, 0. 428)
y<-c(y, betaO+beta1+s1+rnorm(1,0,0.06), betaO+beta2+s1+rnorm(1,0,0.06»
}

for (j in (n1+1): (n1+n2»
{Sub<-c(Sub, rep(j, 2»
TC<-c(TC, "C", "T")
Period<-c (Period, 1,2)
sl<-rnorm(1,0,0.428)
y<-c(y, betaO+s1+rnorm(1,0,0.06), betaO+beta1+beta2+beta12+s1+rnorm(1,0,0.06»
}

Period<-factor(Period); TC<-factor(TC)
temp<-summary(lme(y~Period*TC,random=~lISub»

beta1. Ime[iterJ<-temp$tTable[3, 1J
reject.lme[iterJ<-ifelse(temp$tTable[3, 5J<0. 05, 1, 0)
y1l<-y[2*(1:n1)-1]; y12<-y[2*(1:nl)J
y21<-y[2*«n1+l): (n1+n2»-1]; y22<-y[2*«n1+1): (n1+n2»]
sum1 <-yll +y12
sum2<-y21+y22
meandiff. sum[iter] <-mean (suml)-mean(sum2)
var. sd[iter] <-sqrt «var(suml)*(nl-l)+var(sum2)*(n1-l»/(2*nl-2)*(2/nl»
stat. sum<-meandiff. sum[iter]/var. sd[iter]
aa<-2*pt(-abs(stat. sum),2*nl-2)
if (aa)O. 1) {
diff! <-yll-y12
diff2<-y21-y22
yy<-c(diffl,diff2)
yy.mean[iterJ<-(mean(diffl)-mean(diff2»*0.5
yy. sd<-sqrt«var(diffl)*(n1-1)+var(diff2)*(n1-1»/(2*nl-2)/(2*n1»
t. statistic<-(yy.mean[iterJ)/yy. sd
if(2*pt(-abs(t. statistic), (2*nl-2»<0. 05) {Count. trad<-Count. trad+1}
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}

if (aa<O. 1) {
Count. carry<-Count. carry+1
yy.mean[iter]<-mean(y11)-mean(y2I)
p.value<-t. test(yII, y2I)$p.value
if(p. value<O. 05) {Count. trad<-Count. trad+1}
}
}

sum (reject. Ime)/1000
mean (betal. lme); sd(beta1.1me)
Count. carry/1000
Count. trad/lOOO
mean (yy. mean) ; sd(yy.mean)
par (mfrow=c (3, 2), mai=c(O. 4,0.4, 0.4,0.1)
y<-c(0.8II,0. 308,0.045,0. 305,0.831)
x<-c(-0.6,-0. 3,0,0. 3,0.6)
plot(y~x,xaxt="n",main="A1:

n=lO,

B 12=0", ylab=" power", xlab=" B 1", ylim=c (0, 1), type=" 1")
axis(side=I,at=c(-0.6,-0. 3,0,0.3,0.6), labels=c(-0.6,-0.3,0,0.3,0.6»
par (new=TRUE)
b<-c(O. 94, 0. 948,0.086,0.943,0.972)
plot (b ~x, xaxt=" n", type="l", lty=2, ylim=c (0, 1), ylab=" power", xlab=" B 1")
axis(side=I, at=c(-O. 6,-0. 3,0,0. 3,0.6), labels=c(-0.6,-0. 3,0,0. 3,0.6»
m<-c(0.999,0. 755,0.044,0. 768,0. 999)
n<-c(O. 999,0. 943,0. 103,0.948,0.999)
plot(m~x,xaxt="n",main="A2:

n=30,

B 12=0", ylab="power", xlab=" B 1", ylim=c (0,1), type="l")
axis(side=I, at=c(-O. 6,-0. 3,0,0. 3,0.6), labels=c(-0.6,-0.3,0,0.3,0.6»
par (new=TRUE)
plot(n~x,xaxt="n",type="l", Ity=2,ylim=c(0, 1), ylab="power", xlab="B 1")
axis(side=I,at=c(-0.6,-0.3,0,0.3,0.6), labels=c(-0.6,-0.3,0,0.3,0.6»
p<-c(o. 826,0. 299,0. 054,0. 324,0.858)
q<-c(0.998,0.762,0.287,0.698,0.866)
plot(p~x,xaxt="n",main="BI:

n=10,

B 12=0.5", ylab="power", xlab=" B 1", ylim=c(O, 1), type="l") .
axis(side=I, at=c(-O. 6,-0. 3,0,0. 3,0.6), labels=c(-0.6,-0.3,0,0.3,0.6»
par (new=TRUE)
plot (q ~ x, xaxt=" n", type=" 1", 1ty=2, ylim=c(O, 1), ylab=" power", xlab=" B 1")
e<-c(0.999,0. 739,0.051,0. 741,0.999)
f<-c(O. 999, 0. 996,0. 34,0. 742,0.999)
. "B2 :
p1ot (e~ x,xaxt="
n"
,maIn=
B 12=0.5", ylab="power", xlab=" B 1", ylim=c(O, 1), type="l")
axis(side=I, at=c(-O. 6,-0. 3,0,0. 3,0.6), labels=c(-0.6,-0.3,0,0.3,0.6»
par (new=TRUE)
plot (f~ x, xaxt=" n", type=" 1", 1ty=2, ylim=c (0, 1), ylab=" power", xlab=" B 1")
u<-c(o. 824, 0. 301,0. 047,0. 312,0.823)
v<-c(O. 997,0.488,0.228,0. 346,0. 82)
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n=30,

plot(u~x,xaxt="n",main="Cl:

n=10,

/3 12=1. 0", ylab=" power", xlab=" /3 1", ylim=c (0, 1), type="l")
axis(side=l, at=c(-O. 6,-0. 3,0,0. 3,0. 6), labels=c(-0.6,--0. 3,0,0.3,0.6»
par (new=TRUE)
plot(v~x, xaxt="n", type="l", lty=2, ylim=c(O, 1), ylab="power", xlab=" /31")
j<-c(0.999,0. 753,0.056,0. 774,0.999)
k<-c(0.999,0. 754,0.157,0.705,0.999)
plot(j~x,xaxt="n",main="C2:

n=30,

/312=1. 0", ylab="power", xlab=" /3 1", ylim=c(O, 1), type="l")
axis(side=l,at=c(-O. 6,-0.3,0,0. 3,0.6), labels=c(-0.6,-0.3,0,0.3,0.6»
par (new=TRUE)
plotCk ~ x, xaxt=" n", type="l", I ty=2, ylim=c (0, 1), ylab=" power", xlab=" /3 1")

************************************************************************
Analysis for PM!AIR data

************************************************************************
library (nlme)
x<-read.csv(file="c:/r.csv")
a<-as.data. frame(x[,c("subject", "Time", "ExposureAtmosphere", "Period", "X4th")])
attach (a)
par (mfrow=c (4, 4»
for (i in 1: 13) {
plot (X4th[(6*i-5) : (6*i-3)], type="b",col="red")
par (new=TRUE)
plot (X4th[ (6*i -2) : (6*0], type="b", col ="blue", I ty=2)
}

par (mfrow=c (1, 1»
plot (a$X4th[a$Time!="Pre"&a$ExposureAtmosphere=="PM"],
type="l", col="red", ylim=c(0,400),xlim=c(0,30),xlab=" ", ylab="CD31+CD34+/50K lymph")
par (new=TRUE)
plot (a$X4th [a$Time !="Pre"&a$ExposureAtmosphere=="AIR"] ,
type="l",col="blue", lty=2, ylim=c(O, 400), xlim=c(O, 30), xlab=" ",ylab="CD31+CD34+/50K
lymph")
legend ("topleft", legend=c("PM", "AIR"), Ity=c(1,2),col=c("red", "blue"»
aa<-a[1:42,]
attach (aa)
par (mfrow=c (1, 2»
for(iin1:7){
plot (X4th[(6*i-5) : (6*i-3)], type="l", Ity=(i+1),ylim=c(20,300),ylab="CD31+CD34+/50K
lymph",xlab=" ",main="PM in sequence PM/AIR")
par (new=TRUE)
}

m1<-mean(X4th[Period==1&Time=="Pre"])
m2<-mean(X4th[Period==1&Time=="Post"])
m3<-mean(X4th[Period==1&Time=="FU"])
plot(c(m1,m2,m3), type="I",ylim=c(20,300),col="red",ylab="CD31+CD34+/50K
lymph",xlab=" ", Iwd=4)
forCi in 1:7) {
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plot (X4th[(6*i-2) : (6*i)], type="l", Ity=(i+1),ylim=c(20,300),ylab="CD31+CD34+/50K
lymph",xlab=" ",main="AIR in sequence PM/AIR")
par (new=TRUE)
}

m4<-mean(aaa$X4th[Period==2&Time=="Pre"])
m5<-mean(aaa$X4th[Period==2&Time=="Post"])
m6<-83.8328
plot(c(m4,m5,m6), type="l", ylim=c(20,300),col="green", ylab="CD31+CD34+/50K
lymph",xlab=" ", Iwd=4)
par(mfrow=c(1,2»
a. back<-a[43:72,]
for(i in 1:5) {
plot (a. back$X4th[(6*i2): (6*i)],type="I", Ity=(i+l),ylim=c(20,800),ylab="CD31+CD34+/50K
lymph",xlab="
",main="PM in sequence AIR/PM")
par (new=TRUE)
}

m11<-na.omit(a. back$X4th[Period==2&Time=="Pre"])
mean (ml1)
m22<-na.omit(a. back$X4th[Period==2&Time=="Post"])
mean (m22)
m33<-na.omit(a. back$X4th[Period==2&Time=="FU"])
mean (m33)
plot(c(mean(ml1),mean(m22),mean(m33», type="l", ylim=c(20,800),col="red",ylab="CD31
+CD34+/50K lymph",xlab=" ",lwd=4)
for(iinl:5){
plot (a. back$X4th[(6*i-5): (6*i3) J, type="l", I ty= (i +1), ylim=c (20,800), ylab="CD31 +CD34+/50Klymph", xlab="
",main="AIR in sequence AIR/PM")
par (new=TRUE)
}

m44<-na.omit(a. back$X4th[Period==1&Time=="Pre"])
m66<-na. omit (a. back$X4th[Period==I&Time=="FU"])
m55<-na.omit(a. back$X4th[Period==1&Time=="Post"])
plot(c(mean(m44),mean(m55),mean(m66», type="l", ylim=c(20,800),col="green",ylab="CD
31+CD34+/50K lymph",xlab="", Iwd=4)
for (i in 1: 27) {
z[2*i-l] <-a$X4th[3*i-1]-a$X4th[3*i-2]
z[2*i]<-a$X4th[3*i]-a$X4th[3*i-2]
}

y1.omit<-which(a$Time=="Pre")
y1.reduced<-a[-y1.omit, ]
y. full<-data. frame(y1.reduced,z)
z. treat< -c(rep (c(1, 1,0,0), 7), rep (c (0,0, 1, 1),5), c(0, 0, 1, 1, 1, 1)
z. time<-rep(c(O, 1),27)
z. period<-c (rep(c (0, 0,1,1),13), c(1, 1)
y. final<-data. frame(y. full, z. treat,z. time,z.period)
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library (nlme)
abc<-lme(z~z.

treat*z.

time*z.period,random=~llsubject,data=y.

ra. exclude" )
summary (abc)

36

final,ra.action=
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